**REPUBLIC OF LEBANON** MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

# Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

13/08/2025 19:29:24

Primary registry identifying number	Protocol number
Primary registry identifying number	
BCTR2019020198	SEG101B2201
IOH registration number	
study registered at the country of origin	Study registered at the country of origin: Specify
/es	
Type of registration	Type of registration: Justify
Prospective	N/A
Date of registration in national regulatory agency	
Primary sponsor	Primary sponsor: Country of origin
Novartis Pharma Services Inc.	Novartis Pharmaceuticals
Date of registration in primary registry	Date of registration in national regulatory agency
03/09/2020	
Public title	Acronym
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients	
Scientific title	Acronym
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso- Occlusive Crisis	
Brief summary of the study: English	
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in bediatric patients ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was already demonstrated in adults with sickle cell disease. The approach is to extrapolate from he PK/pharmacodynamics (PD) already established in the adult population. The study is designed as a Phase II, multicenter, open- abel study.	
Brief summary of the study: Arabic	
ئز ، في المرحلة الثانية لتقبيم الجر عات المناسبة وسلامة دواء كريز انليز وماب، مع أو بدون هيدروكسم م مصابين بداء الكريات المنجليّة لدى الأطفال مع نوبة انسداد و عانيّ من فنات عمريّة تسلسليّة وتنازليّ	
Health conditions/problem studied: Specify	

### Interventions: Specify

Drug: Crizanlizumab Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL.

Bir Hassan, Jnah, next to Ogero Beirut- Lebanon clinicaltrials@moph.gov.lb

One vial contains 100 mg of crizanlizumab.

Other Name: SEG101

### Key inclusion and exclusion criteria: Inclusion criteria

REPUBLIC OF LEBANON

MINISTRY OF PUBLIC HEALTH

•Male or female patients aged 2 to <18 years (Group 3 will be expanded to allow enrolment of patients aged 6 to <24 months (and at least 6 kg) in Part B once the appropriate dose is confirmed in 2 to <6 year old patients)

•Confirmed diagnosis of sickle cell disease (SCD) (e.g. any genotype including HbSS, HbSC, HbSβ0-thalassemia, HbSβ+-thalassemia, and others) by hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) performed locally.

•Experienced at least 1 VOC within the preceding 12 months, as determined by medical history. Prior VOC must have resolved at least 7 days prior to the first dose in the study and should include all the following:

1.the occurrence of appropriate symptoms (see VOC definition in protocol Section 7.2.1.1)

2.either a visit to a medical facility or healthcare professional,

3.receipt of oral/parenteral opioid or other non-opioid parenteral analgesia.

•If receiving HU/HC or erythropoietin stimulating agent, must have been receiving the drug for at least 6 months prior to Screening and plan to continue taking at the same dose and schedule during the trial. Dose alterations of HU/HC during Part A are not allowed, and if this occurs, the patient will enter directly to the Part B.

•Received standard age-appropriate care for SCD, including penicillin prophylaxis, pneumococcal immunization, and parental education •Transcranial Doppler (TCD) considered low risk within the past 6 months (for 2 to 16 years).

### Key inclusion and exclusion criteria: Gender

Key inclusion and exclusion criteria: Age maximum

Key inclusion and exclusion criteria: Specify gender

18

### Key inclusion and exclusion criteria: Exclusion criteria

Key inclusion and exclusion criteria: Age minimum

•History of stem cell transplant.

Both

1

•Received any blood products within 30 days of Day 1 dosing.

•Participating in a chronic transfusion program (preplanned series of transfusions for prophylactic purposes).

Patients with bleeding disorders

•Planning on undergoing an exchange transfusion during the duration of the study. Patients requiring episodic transfusion in response to worsened anemia or VOC are permitted.

•Contraindication or hypersensitivity to any drug from similar class as study drug or to any excipients of the study drug formulation.

•Received a monoclonal antibody or immunoglobulin-based therapy within 6 months of Screening, or has documented immunogenicity to a prior monoclonal antibody.

•Received active treatment on another investigational trial within 30 days (or 5 half lives of that agent, whichever is greater) prior to Screening or plans to participate in another investigational drug trial.

•Pregnant females or females who have given birth within the past 90 days or who are breastfeeding.

•Any documented history of a stroke or intracranial hemorrhage, or an uninvestigated neurologic finding within the past 12 months •Any conditional TCD within the past 12 months

•Use of therapeutic anticoagulation (prophylactic doses permitted) or antiplatelet therapy (other than aspirin) within the 10 days prior to Week 1 Day 1 dosing

•Hospitalized at Screening

•Planning to undergo a major surgical procedure during the duration of the study

•Planning to initiate or terminate HU/HC while on study, other than for safety reasons

•Patient with active HIV infection (detectable viral load)

•Patients with known active Hepatitis B infection.

•Patients with known Hepatitis C history.

•Significant active infection or immune deficiency (including chronic use of immunosuppressive drugs) in the opinion of the investigator.

•Malignant disease. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; any completely resected carcinoma in situ.

+Has a serious mental or physical illness, which, in the opinion of the Investigator would compromise participation in the study.

•Resting QTcF ≥450 msec at pretreatment (baseline) for patients under 12 years of age and ≥450 msec for males and ≥460 msec for female patients 12 years and older.

•Cardiac or cardiac repolarization abnormality

•Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome

•Sexually active females who are unwilling to comply with reliable method of birth control until 15 weeks following last dose of study drug.

•Current drug or alcohol abuse:

1.Has a positive qualitative urine drug test at Screening for cocaine, phencyclidine (PCP), or amphetamines (opioids are permitted). 2.Consumes >12 (for males) or >8 (for females) standard alcoholic beverages per week.

•Not able to understand and to comply with study instructions and requirements.

•Subjects, who are an employee of the sponsor or investigator or otherwise dependent on them.

•Subjects, who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.

Type of study



## Lebanon Clinical Trials Registry

# REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Interventional		
Type of intervention Pharmaceutical	Type of intervention: Specify ty N/A	уре
Trial scope Other	Trial scope: Specify scope	
Study design: Allocation N/A: Single arm study	Study design: Masking Open (masking not used)	
Study design: Control N/A	Study phase 2	
Study design: Purpose Prevention	Study design: Specify purpose N/A	
Study design: Assignment Single	Study design: Specify assignm	ient
IMP has market authorization No	IMP has market authorization:	Specify
Name of IMP SEG101 - Crizanlizumab	Year of authorization	Month of authorization
Type of IMP Immunological		
Pharmaceutical class anti-human P-selectin antibody G1		
Therapeutic indication prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with	sickle cell disease (SCD)	
Therapeutic benefit 1.Number of Vaso Occusive Crisis (VOC) events leading to healthcare visit 2.Number of Vaso Occusive Crisis (VOC) events treated at home 3.Number of each subcategory of VOC event (uncomplicated pain crisis, ac hepatic sequestration, splenic sequestration, priapism)	•	
Study model	Study model: Explain model	
N/A Study model: Specify model N/A	N/A	
Time perspective N/A	Time perspective: Explain time N/A	e perspective
Time perspective: Specify perspective N/A		
Target follow-up duration	Target follow-up duration: Unit	



# Lebanon Clinical Trials Registry

Number of groups/cohorts

Biospecimen retention Samples without DNA **Biospecimen description** 

All Blood samples and Urine Samples will be shipped to Covance Geneva Central Lab

Target sample size

5

Date of first enrollment: Type
Actual

Date of study closure: Type Actual

Recruitment status Suspended

Date of completion 31/07/2020

IPD sharing statement plan No Actual enrollment target size 3

Date of first enrollment: Date 13/12/2019

Date of study closure: Date 20/07/2022

**Recruitment status: Specify** 

### IPD sharing statement description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

### Additional data URL


https://clinicaltrials.gov/ct2/show/NCT03474965?term=seg101&rank=2

Admin comments

### Trial status

Approved

Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
Clinical Trials. gov	NCT03474965	





### **Sources of Monetary or Material Support**

### Name

Novartis Pharma Services Inc.

### **Secondary Sponsors**

Name

NA

Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Adlette Inati	Tripoli	Lebanon	009613228 033	adlette.inati@lau. edu.lb	Nini Hospital
Scientific	Hind Khairallah	Sin El Fil	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l.
Public	Miguel Abboud	Beirut	Lebanon	00961 (0) 3 534 213	ma56@aub.edu.l b	American University of Beirut Medical Center

Centers/Hospitals Involved in the Study			
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Nini Hospital	Dr Adlette Inati	Hematology	Approved
American University of Beirut Medical Center	Dr Miguel Abboud	Hematology	Approved

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Nini Hospital	17/12/2018	Nabil Kabbara	Nabil.kabbara@hopitalnini.com	+961 (0) 6 431 400 ext 1062
American University of Beirut Medical Center	16/10/2019	Fuad Ziyadeh	fz05@aub.edu.lb	+961 (0) 1 350 000 ext:5445






Countries of Recruitment
Name
Lebanon
Belgium
Germany
India
United States of America
Canada
Colombia
France
Italy
Oman
Spain
Switzerland
Turkey
United Kingdom

Health Conditions or Problems Studied		
Condition Code Keyword		Keyword
Sickle Cell Disease	Sickle-cell disorders (D57)	SCD

Interventions		
Intervention	Description	Keyword
Please refer to table 7- 1 in the attached Protocol V00, page 51Consenting process, Physical Exam, Vital Signs, Medical History, Lab assessments, efficacy assessments and Biomarker assessments, pharmacokinetics and immunogenicity	Consenting process, Physical Exam, Vital Signs, Medical History, Lab assessments, efficacy assessments and Biomarker assessments, pharmacokinetics and immunogenicity	ICF, IMP, Lab





Primary Outcomes			
Name	Time Points	Measure	
PK (AUCd15) after 1st dose, Confirm appropriate dosing of crizanlizumab in patients aged 2 to < 18 years	15 days	15 days	
•PK (AUCtau) after 5th dose	week 15	week 15	
<ul> <li>Frequency of any adverse events (AEs) as a measure of safety and tolerability</li> </ul>	6 months , 2 years	6 months , 2 years	

### **Key Secondary Outcomes**

Rey decondary outcomes			
Name	Time Points	Measure	
<ul> <li>Number of Vaso Occusive Crisis (VOC) events leading to healthcare visit in clinic/ER/hospital</li> </ul>	6 months, 2 years	6 months, 2 years	
<ul> <li>Number of Vaso Occusive Crisis (VOC) events treated at home (based on documentation by health care provider following phone contact with the patient)</li> </ul>	6 months, 2 years	6 months, 2 years	
•Number of hospitalizations and ER visits (both overall and VOC-related)	6 months, 2 years	6 months, 2 years	
•Absolute change from baseline in hemoglobin	Baseline, 6 months, 2 years	Baseline, 6 months, 2 years	



# Trial Results Summary results Study results globally Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files